Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Posted: August 14, 2024 at 2:37 am

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.

The rest is here:
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Related Posts